News

In March 1984, people were irradiated at PSI for the first time against a rare but very malignant type of cancer: They had a tumour in their eye.

A promising radiopharmaceutical against metastatic neuroendocrine tumours – developed at the Paul Scherrer Institute PSI – has been successfully tested.

Daniela Kiselev talks about the upgrade planned at PSI's proton accelerator facility.

PSI researchers take pictures of cell nuclei using modern high-resolution imaging techniques, employ learning algorithms to comb through these data, and thus can more reliably identify anomalies.

Each cell in the human body contains a cytoskeleton. Contrary to what the name suggests, the cytoskeleton is far more than just a support structure.

The cytoskeleton is a little marvel. Probing it promises to reveal, among other things, new possibilities for cancer therapy.

Synchrotron light can be used in follow-up after a heart transplant to determine whether the body may be rejecting the new organ.

TATTOOS is part of the upgrade project IMPACT. Roger Schibli explains its importance for the future of cancer treatment.

A two-part upgrade is planned for HIPA starting in 2025. Preparations are already under way.

From research to production – the new pharmaceutical lab at PSI supplies neighbouring hospitals with novel cancer drugs.

Employing high-resolution X-rays to diagnose breast cancer – PSI researchers nominated for the European Inventor Award.

PSI is involved in the development of a breath test that can be used to diagnose asthma. Imad El Haddad explains why such a test could be extremely useful – especially for children.

This gallery presents five people who have been treated at the PSI's Center for Proton Therapy.

The University Hospital of Zurich uses proteins made at PSI for Europe’s first large-scale serology study on coronavirus prevalence in Switzerland.

Crystal structure analysis, computer models, cell cultures – to pursue research on Sars-CoV-2, PSI is exploring many avenues. An overview.

A research consortium has deciphered the mechanism of CCR5 receptor activation, providing insights for the development of CCR5 drug antagonists for AIDS, cancer, and inflammatory diseases.

Researchers at Goethe University Frankfurt, in cooperation with the PSI have probably discovered another, previously unknown mechanism of action of the antiviral remdesivir.

Imaging and sequencing techniques combined with machine learning offer researchers countless opportunities to look inside cells with greater precision than ever before. G.V. Shivashankar, lab head at PSI, describes how such information can be used to find answers to pressing questions.